Fifty 1 Labs, Inc. is a Nevada-based holding company focused on health, wellness, and biotech through AI-driven drug repurposing and functional medicine. The Company operates subsidiaries including Fifty1 AI Labs LLC and 51 Labs LLC, which focus on personalized medicine, sports nutrition, and advanced therapeutics. Fifty1 AI Labs LLC delivers transformative solutions for patients and shareholders. 51 Labs LLC offers a line of supplements including pre-workout formulas, BCAAs, ION+ Electrolyte Formula, Turmeric Gummies, and Ashwagandha Gummies designed to enhance athletic performance, recovery, and overall health.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-12	0.000500 $	-16.67%	9,058,029
26-06-11	0.000600 $	+100.00%	100,143,723
26-06-10	0.000300 $	0.00%	5,767,300
26-06-09	0.000300 $	0.00%	5,026,554
26-06-08	0.000300 $	0.00%	10,707,000

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets Other stock markets 15:59:57 2026-06-12 EDT			5-day change	1st Jan Change
0.000500 ^USD	-16.67%		+66.67%	-

01-05	Fifty 1 Labs, Inc. Announces CEO Changes	CI
25-08-14	Fifty 1 Labs, Inc. Announces the Completion of the Largest and Most Comprehensive Study of Sickle Cell Disease	CI

Market Cap	281K 243K 224K 210K 393K 26.76M 399K 2.65M 1.03M 13.02M 1.06M 1.03M 45.09M	P/E Ratio 2009	-0.05x	P/E Ratio 2010	-0.01x
Enterprise Value	12.55M 10.84M 9.99M 9.35M 17.53M 1.19B 17.8M 118M 46M 581M 47.12M 46.11M 2.01B	EV / Sales 2009	1.86x	EV / Sales 2010	2.41x
Free-Float	57.9%	Yield 2009 *	-	Yield 2010	-

01-05	Fifty 1 Labs, Inc. Announces CEO Changes	CI
25-08-14	Fifty 1 Labs, Inc. Announces the Completion of the Largest and Most Comprehensive Study of Sickle Cell Disease	CI
25-07-10	Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling 50 1 Labs, Inc. Toward $50 Million Valuation	CI
25-04-30	Fifty 1 Labs, Inc. Appoints Michael Lawson as Chairman of the Board	CI
25-04-30	Fifty 1 Labs, Inc. Appoints Michael Lawson as Chief Executive Officer	CI
25-04-30	The Fifty 1 Labs Biosentry Division Will Develop State-Of-The-Art Biohazard Sensing Sensors Capable of Detecting Pathogens	CI
25-04-30	UAV Corp. Announces Strategic Partnership with 50 1 Labs, Inc	CI
25-04-08	Uav Corp And Genetic Networks Announce Strategic Collaboration	RE
25-03-20	Fifty 1 Labs, Inc. Appoints Gennaro D'Urso as CEO	CI
25-03-20	Fifty 1 Labs, Inc. Appoints Gennaro D'urso as Chairman	CI
25-03-19	Fifty 1 Labs, Inc. acquired Genetic Networks, LLC for $0.02 million.	CI
25-03-14	Consumer Automotive Finance, Inc has Changed its Name to Fifty 1 Labs, Inc	CI
25-03-14	Fifty 1 Labs, Inc. has Changed its Ticker to FITY from CAFI	CI

04-15	Fifty 1 Labs, Inc. Accelerates Peptide Biotechnology Push into Musculoskeletal Health	AQ
04-14	Fifty 1 Labs, Inc. Eliminates 612 Million Shares from the Market	AQ
01-05	Fifty1 Labs, Inc. Clarifies Status Regarding Previously Announced Collaboration with LUNR Aerospace	AQ
25-10-09	Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer	AQ
25-09-30	Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc.	AQ

Fifty 1 Labs, Inc. Stock

Stocks

FITY

US2104931025

Biotechnology & Medical Research

Valuation: Fifty 1 Labs, Inc.

Chart: Fifty 1 Labs, Inc.

Latest news : Fifty 1 Labs, Inc.

Press Releases: Fifty 1 Labs, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Fifty 1 Labs, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 day	-16.67%
1 week	+66.67%
Current month	+66.67%
1 month	+66.67%
3 months	+25.00%
6 months	-50.00%

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.01
3 years	0		0.12
5 years	0		0.23
10 years	0		0.23

Manager	Title	Age	Since
Pritpaul Singh Arora CEO	Chief Executive Officer	47	-
Brandon Spikes PSD	President	-	-
Alind Gupta CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Robert Clark BRD	Director/Board Member	49	2025-04-29
Brandon Spikes CHM	Chairman	-	2023-07-11
Curtis Young BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FIFTY 1 LABS, INC.	-16.67%	+66.67%	-88.37%	-97.71%	592K
LONZA GROUP AG	-0.35%	+0.97%	-13.80%	-13.83%	43.03B
REVOLUTION MEDICINES, INC.	+3.11%	+3.11%	+279.08%	+509.39%	32.71B
IQVIA HOLDINGS INC.	+0.22%	-1.08%	+15.66%	-14.70%	30.29B
BEONE MEDICINES AG	+1.62%	-2.08%	-1.91%	+27.08%	29.4B
CELLTRION, INC.	+4.09%	+0.93%	+12.97%	+20.66%	25.08B
ASCENDIS PHARMA A/S	+1.14%	+3.62%	-	-	13.54B
MEDPACE HOLDINGS, INC.	-1.63%	+2.88%	+56.69%	+114.08%	13.35B
EUROFINS SCIENTIFIC SE	-0.40%	-1.29%	+6.23%	+6.41%	12.97B
IONIS PHARMACEUTICALS, INC.	-0.74%	-1.62%	+105.89%	+79.51%	12.11B
Average	-0.96%	+7.97%	+41.38%	+70.10%	21.25B
Weighted average by Cap.	+1.05%	+1.48%	+57.30%	+98.05%

	2009	2010
Net sales	5.41M 4.67M 4.31M 4.03M 7.56M 514M 7.67M 50.86M 19.83M 250M 20.31M 19.88M 867M	5.11M 4.41M 4.06M 3.8M 7.13M 485M 7.24M 47.99M 18.71M 236M 19.16M 18.76M 818M
Net income	-2.23M -1.93M -1.78M -1.66M -3.12M -212M -3.16M -20.97M -8.18M -103M -8.37M -8.2M -357M	-1.89M -1.64M -1.51M -1.41M -2.64M -180M -2.69M -17.8M -6.94M -87.64M -7.11M -6.96M -303M
Net Debt	9.96M 8.6M 7.92M 7.42M 13.9M 946M 14.12M 93.56M 36.48M 461M 37.36M 36.57M 1.59B	12.27M 10.6M 9.77M 9.14M 17.14M 1.17B 17.4M 115M 44.97M 568M 46.06M 45.08M 1.97B